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Pharmacology of Antiparkinsonian Agents
Robert P. Soltis 1
College of Pharmacy and Health Sciences, Drake University, Des Moines I A 50311
PROLOGUE

The following is a summary of a two hour class on the basic
pharmacology of antiparkinsonian agents. It is presented to
fourth-year pharmacy students in pharmacotherapeutics
III, a course structured using team-taught modules. Faculty
from the Department of Pharmacy Sciences provide instruction on the basic pharmacology of therapeutic agents
and faculty from the Department of Pharmacy Practice
follow up with a discussion of the therapeutic applications of
these agents. This course is lecture-based with opportunities
for in-class discussion.
One week prior to the lecture sequence on the basic
pharmacology of antiparkinsonian drugs, students are provided a handout that includes the reading assignment (1),
learning objectives and a topic outline. The topic outline
contains the chemical structures of the agents to be discussed as well as the figures, patient scenarios and study
questions appearing in this manuscript. During each 50minute period, material is presented as a lecture tied to
patient scenarios. The scenarios are presented in class immediately after covering the pharmacological concepts to
which they apply. Students are asked to discuss in small
groups potential solutions to the scenarios and to offer their
answers to the rest of the class on a volunteer basis. The
study questions are geared for preparing for exams and are
not discussed in class unless students request. At the end of
these two lectures, a homework problem is assigned that
introduces the 6-hydroxydopamine rat model of Parkinson’s
disease. The following week, a live demonstration related to
the homework is presented in class with a short discussion
afterwards.
The objectives of these classes focus on understanding
the pharmacological mechanisms of drug therapy for
Parkinson’s disease and using this information to predict or
solve drug-related problems. Specifically, the student should
be able to: (i) describe the symptoms and neuropathology
associated with Parkinson’s disease; (ii) discuss how current
drug therapy and the different mechanisms of action are
useful in the treatment of Parkinson’s disease; (iii) understand how the course and the severity of the disease can
affect drug therapy; and (iv) predict potential side effects
and drug interactions and suggest ways to alleviate these
problems based on pharmacological and pharmacokinetic
concepts.
PARKINSON’S DISEASE

Parkinson’s disease is a disorder of the central nervous
system that is characterized by three cardinal features: (i)
bradykinesia (slowness of movement); (ii) muscular rigidity; and (iii) resting tremor that stops upon voluntary movement. Other symptoms that may occur include stooped
1
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Fig. 1. Neuronal projections from the motor cortex and substantia
nigra to the striatum in normal (left) and parkinsonian patients
(right). Minus signs (-) represent the inhibitory actions of dopamine
(DA); plus signs represent the excitatory actions of acetylcholine
(Ach) and glutamate (Glu) in the striatum.

posture with a characteristic shuffling gait, sialorrhea and
dementia during the later stages of the disease (2-5).
The disease is characterized by a selective loss or degeneration of the nigrostriatal pathway. This pathway consists
of neurons that project from the substantia nigra to the
striatum and use dopamine as the neurotransmitter (Figure
1). Acetylcholine and glutamate are also present as neurotransmitters in the striatum but are unaffected by the
disease. As a consequence, there is an imbalance between
the inhibitory actions of dopamine and the excitatory actions of acetylcholine and glutamate in the striatum. All of
the major symptoms seen in Parkinson’s disease appear to
be attributed to this imbalance. Interestingly, the symptoms
of Parkinson’s disease do not present until 70-80 percent of
the dopamine neurons in the nigrostriatal tract are lost. This
suggests that a large redundancy of the nigrostriatal pathway or compensatory mechanisms in other pathways exist
that correct for the loss of nigrostriatal pathway until a
critical point is reached (4, 6).
Typically the symptoms of Parkinson’s disease do not
occur until after age 55 and affect approximately one percent of the elderly population worldwide. If the disease is
left untreated, patients become rigid and akinetic. As the
disease progresses, Parkinsonian patients lose the ability to
care for themselves and suffer from complications associated with immobility such as pulmonary embolism and
pneumonia (5).
The cause of Parkinson’s disease is unknown. Several
theories have been suggested including a genetic link, toxins
and oxidative stress. It appears that in the vast majority of
cases, the disease is not genetically determined. While there
are well documented cases of families with a high incidence
of Parkinson’s disease, these cases constitute only a small
fraction of Parkinsonian patients (3-5,7,8).
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Fig. 2. Relative amounts of dopamine (DA) and acetylcholine (Ach) in
the striatum of normal (left) and parkinsonian patients (right).
Addition of a dopamine agonist or an anticholinergic agent attempts
to restore the proper balance between DA and Ach in the
Parkinsonian patient.

Normal adults experience approximately one percent
loss of striatal dopamine per year. Given that Parkinsonian
symptoms do not appear until later in life and only until after
70 percent or more of striatal dopamine is depleted, it is
possible that Parkinson’s disease results from two processes;
a specific disease-related insult that does not reduce the
dopamine content to symptomatic levels combined with the
gradual loss of neurons during normal aging. This may
explain why Parkinson’s disease is a progressive disorder of
late onset. Thus, the progression of symptoms may not
necessarily be the result of an active disease process but
rather may be the effects of aging superimposed on the
initial insult. That is, the neuronal destruction may have
occurred early in life but the symptoms do not appear until
later in life when additional neurons are lost during normal
aging (4).
Certain drug therapies can also produce Parkinsonianlike symptoms. Most notable are dopamine receptor antagonists used in the treatment of schizophrenia (haloperidol,
chlorpromazine) and emesis (metoclopramide,
prochlorperazine). The antihypertensive agent reserpine
can also produce Parkinsonian-like symptoms because of its
ability to deplete neuronal stores of dopamine. By preventing the uptake of dopamine into storage vesicles, reserpine
makes dopamine available for destruction by monoamine
oxidase (MAO) present within the nerve terminal. The
Parkinsonian-like symptoms associated with these drugs are
reversible and subside upon discontinuing the drug or decreasing the dose.
PHARMACOTHERAPY

Symptoms associated with Parkinson’s disease result from
an imbalance between dopamine (deficiency) and acetylcholine (excess). Current drug therapy focuses on restoring
the balance between these two neurotransmitters. In theory,
any drug that can penetrate the blood brain barrier and
produce an effect that results in the activation of dopamine
receptors or in the blockade of muscarinic receptors should
be of value in treating Parkinson’s disease. The diagram in
Figure 2 depicts the relative amounts of dopamine and
acetylcholine in normal and Parkinsonian patients. Addition of either a dopamine agonist or an anticholinergic
(muscarinic antagonist) in a Parkinsonian patient helps to
restore the proper balance between these two neurotransmitters. Bear in mind that the current drug therapies treat
only the symptoms of the disease; they do not cure or appear
to alter the long term course of the underlying disease.
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Fig. 3. Synthetic and metabolic pathways of dopamine.

L-DOPA
Levo-dihydroxyphenylalanine (L-DOPA) is the amino
acid precursor to dopamine. It is absorbed through the
blood brain barrier by an active transport system. Once into
the brain, L-DOPA is taken up into the nerve terminal and
decarboxylated by aromatic L-amino acid decarboxylase
(AAADC) to form dopamine (Figures 3 and 4). Apparently, there are enough surviving neurons for the synthesis
and release of dopamine to occur and produce a therapeutic
effect. Dopamine itself cannot be used because it does not
pass through the blood brain barrier; it is too highly ionized
and is not a substrate for the active transport system. Of all
the L-DOPA administered, about one percent enters the
brain while the remainder is decarboxylated in the periphery. Therefore, 99 percent of the L-DOPA that is administered is wasted in the sense that it is metabolized before it
can get to the site of action in the brain (4).
Study Question
Based on information in Figures 3 and 4, suggest
other drugs or mechanisms which may be useful in
the treatment of Parkinson’s disease.

L-DOPA is rapidly absorbed from the small intestine by
an active transport system for aromatic amino acids. Peak
plasma concentration occurs in 30 to 90 minutes following
oral administration. Plasma half-life is relatively short; 1 to 3
hours. However, the brain half-life is longer because LDOPA is taken up by neurons (protecting it from metabolism) and stored.
One important food-drug interaction with regard to LDOPA involves dietary protein. Ingested proteins are hydrolyzed to amino acids in the gastrointestinal tract prior to their
absorption. These amino acids will compete with L-DOPA
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Fig. 4. Synapse depicting the synthesis, storage, release, post-synaptic receptor interaction, metabolism and reuptake of dopamine.

for absorption carrier sites in the small intestine and slow the
movement of L-DOPA into the blood stream. Pharmacokinetic data substantiate that the administration of L-DOPA
with food delays absorption and reduces peak plasma concentrations. Dietary amino acids can also compete with L-DOPA
for active transport sites at the blood brain barrier. Consequently, the therapeutic effects of intravenously administered L-DOPA can also be influenced by diet (5).
The side effect profile of L-DOPA can be categorized
into early and late occurring events. The most common side
effects that occur early in therapy are nausea and vomiting.
Hypotension and cardiac arrhythmias are also possible in
the initial days of therapy but are not as common. These
initial side effects are peripheral in origin (i.e., do not involve
the CNS) and are mediated by dopamine. L-DOPA itself
has few, if any, pharmacological actions. Therefore, these
side effects can be reduced or eliminated by the addition of a
peripheral inhibitor of AAADC, the enzyme that coverts LDOPA to dopamine (see below). Alternatively, administration of vitamin supplements containing vitamin B6 (pyridoxine), a cofactor for AAADC, will increase the peripheral conversion of L-DOPA to dopamine resulting in more
side effects and a reduced therapeutic effect.
Side effects that occur later in therapy (2-4 months)
include nightmares, hallucinations, psychosis and abnormal, involuntary movements such as dyskinesia or dystonia.
These delayed side effects are of central origin and occur
following administration of relatively high doses. Consequently, these side effects cannot be alleviated by the addition of a peripheral inhibitor of AAADC but instead are
reversed or controlled by reducing the dose. This can be
problematic given that reducing the dose may result in loss
of some of the beneficial effects of therapy (9).
During the first few years of L-DOPA therapy, the
patient usually has smooth, day-long control of the symptoms. However, as the disease progresses, problems begin to
arise. During the course of the day, the patient may experience “peak-dose dyskinesia” which are involuntary movements occurring at the time of peak plasma levels - too much
dopamine. Later in the day, the patient may experience
“end-of-dose hypokinesia”; Parkinsonian symptoms occurring at the time of low or subtherapeutic plasma concentration. These changes are referred to as the “on-off phenom

enon” or the “wearing off phenomenon”. In some instances,
the “on” portion may occur with the rising plasma concentrations rather than the peak concentrations and the “off”
portion occur with the falling concentrations rather than the
troughs. As a result, the on-off in some patients may occur
within relatively short periods of time. In either case, the
motor fluctuations tend to follow the kinetics of L-DOPA
and, therefore, are fairly predictable (3,5).
The theory of why this form of on-off occurs later in
therapy is based on the progressive loss of dopamine neurons. In newly diagnosed patients (i.e., mild Parkinsonism),
there are enough neurons still present to adequately synthesize and store enough dopamine to offset the rise and fall of
L-DOPA plasma concentrations. As the disease progresses,
more neurons die and post synaptic receptors adapt by
upregulating or becoming supersensitive. As a result, with
fewer neurons, the synthetic and storage capabilities of
dopamine are lessened and the sensitivity of the dopamine
receptors is heightened. Now, the range of therapeutic
plasma concentrations of L-DOPA becomes much more
narrow. The peak plasma concentration represents too much
dopamine and produces dyskinesias. The trough concentration represents not enough dopamine and results in
Parkinsonian symptoms. Dietary factors and dosing regimens become very important at this point. Strategies to
reduce the frequency of the on-off phenomenon include low
protein diet, continuous gastric infusion, sustained release
formulations or giving smaller doses more frequently(2).
Another type of on-off phenomenon has been described
in which the fluctuations between mobility and immobility
are random. That is, the changes do not appear to follow the
kinetics of L-DOPA. The mechanism for this form of on-off
is unclear but may involve the interaction of several factors
including pharmacokinetic and pharmacodynamic changes
associated with chronic, high-dose L-DOPA therapy.
Whereas it is possible to treat the predictable fluctuations
with changes in dosage, frequency and route of administration, the random on-off phenomenon is difficult, if not
impossible, to treat(2, 5).
Carbidopa

As stated above, only one percent of an orally administered dose of L-DOPA reaches the CNS because of decarboxylation in the periphery. The conversion of L-DOPA to
dopamine in the periphery is responsible for some of the side
effects associated with L-DOPA therapy. These problems
can be alleviated by administration of carbidopa, a peripheral inhibitor of AAADC. Carbidopa inhibits AAADC by
forming a covalent inhibitory complex with the enzyme’s
cofactor pyridoxal phosphate, a form of vitamin B6 (10).
Carbidopa does not penetrate the blood brain barrier because it is too highly ionized and is not a substrate for the
active transport system. Therefore, it stays in the periphery. If
the drug were to get into the CNS, it would negate LDOPA therapy because L-DOPA would not be converted
to the active form dopamine (4).
The addition of carbidopa to L-DOPA therapy offers a
number of advantages including: (i) reduction in the dose of
L-DOPA by 75 percent; (ii) reduction of all of the peripheral
side effects (but not the central side effects); and (iii) no
need to avoid vitamin B6 supplements. The L-DOPA/
carbidopa combination product is Sinemet®. Rarely will LDOPA therapy be used without carbidopa or some other
inhibitor of AAADC.
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L-DOPA is the most effective drug therapy for
Parkinson’s disease and is considered the mainstay of treatment. Early in the course of the disease, improvement in the
three cardinal features of the disease is nearly complete
along with improvement in handwriting and speech. There
is also an increase in the patient’s sense of well being and
ability to function in society secondary to improvement of
symptoms. However, as the disease progresses, L-DOPA
therapy tends to fail and additional drugs may be added to
the regimen. The drugs discussed below are used primarily
as adjuncts. They may be used alone in the early stages of
Parkinson’s disease but their major role is as add-on therapy
in later stages of the disease (3, 7).
Patient Scenario
DK is a 65 year old female with advanced Parkinson’s
Disease. Her husband cares for her full-time and
confides in you that ever since the physician increased her dose of Sinemet®, she has been acting
goofy; she talks to people who do not exist and she
wants to stay in at night because she claims the night
air makes her hair fall out. Explain why DK is acting
“goofy”. Are there any changes in or additions to
DK’s drug regimen that may alleviate these symptoms?
Bromocriptine (Parlodel®) and Pergolide (Permax®)

Bromocriptine and pergolide are dopamine receptor
agonists. Theoretically, these drugs should offer some advantages over L-DOPA because they do not require active
transport mechanisms for absorption from the GI tract or
for passage through the blood brain barrier. Furthermore,
these drugs do not rely upon functional dopamine nerve
terminals for synthesis and release of the active agent. The
side effect profile of these two agents is similar to L-DOPA;
nausea, vomiting, hypotension but with a potentially higher
incidence of hallucinations than L-DOPA. In addition,
bromocriptine has the potential to produce severe orthostatic hypotension following the first dose(5).
In clinical practice, bromocriptine and pergolide are no
more effective than L-DOPA. The putative selectivity of
bromocriptine for the D2 dopamine receptor subtype does
not appear to offer any therapeutic advantage. (The dopamine receptor family is covered in detail in lectures on schizophrenia where the pharmacology of dopamine receptor
subtypes is better defined with antagonists.) The role in
therapy of these two agents is relegated to use as adjuncts to
L-DOPA therapy during periods of excessive on-off or
when higher doses of L-DOPA are required but cannot be
tolerated(2,5,7).
Amantadine (Symmatrel®)

The mechanism of action of amantadine is not clear. It
appears to cause release and inhibit reuptake of dopamine
(Figure 4). It may have anticholinergic activity as well which
can contribute to its antiparkinsonian effects (Figures 1 and
2). Side effects tend to be relatively mild and include dizziness, nausea and vomiting (3,5).
The use of amantadine is limited to mild cases of
Parkinson’s disease or as an adjunct to L-DOPA. A drawback to its use is its apparent loss of efficacy after 4-8 weeks
of therapy. Interestingly, amantadine was introduced initially (and is still used) for the prevention and treatment of
influenza A. Its potential use as an antiparkinsonian agent
182

was discovered by accident when the Parkinsonian symptoms of patients being treated for the flu improved during
the course of amantadine treatment (4).
Benztropine (Cogentin®) and Trihexyphenidyl (Artane®)

Benztropine and trihexyphenidyl are two examples of
muscarinic cholinergic receptor antagonists. Their mechanism of action with regard to the treatment of Parkinson’s
disease is to block the relative excess of acetylcholine in the
striatum to restore the balance between acetylcholine and
dopamine (Figures 1 and 2). These drugs are helpful in
reducing tremor but not the rigidity or slowness of movement. Side effects of these agents are predictable and are
based on blockade of the parasympathetic nervous system.
In addition, the sedation and mental confusion often associated with anticholinergics tend to be more pronounced in
the elderly and, therefore, an important concern in many
Parkinsonian patients.
Prior to the use of L-DOPA, anticholinergics were the
most effective drugs for the treatment of Parkinson’s disease. Today, anticholinergics are used as adjuncts to LDOPA therapy. They are used in patients with mild forms of
Parkinson’s disease, or in patients who cannot tolerate or
who do not respond to L-DOPA therapy. All anticholinergics used in the treatment of Parkinson’s disease are
equally effective. However, be aware that an individual
patient may tolerate or respond to one preparation better
than another (2,5,7).
Selegiline (Eldepryl®)

Selegiline is a relatively selective inhibitor of monoamine oxidase B (MAO-B). MAO-B is the predominate form
of monoamine oxidase in the striatum and is responsible for
the majority of oxidative metabolism of dopamine in this
region. Consequently, inhibition of this enzyme should result in more dopamine being available for release (Figures 3
and 4). Selegiline is metabolized to amphetamine and
methamphetamine which may also play a role in producing
an antiparkinsonian effect by increasing the release of dopamine (3).
Selegiline is also being looked at as a possible
neuroprotective agent. One theory suggests that the neuronal loss associated with Parkinson’s disease results from
the formation of oxygen free radicals from MAO-mediated
deamination of dopamine. Selegiline has also been shown to
prevent the Parkinsonian syndrome associated with administration of the toxin N-methy1-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) by inhibiting the MAO-B mediated formation of the toxic metabolite 1-methyl-4phenylpyridium (MPP+). If oxygen free radicals or an MPTPlike toxin is responsible for Parkinson’s disease, then
selegiline may be useful in slowing or preventing the progression of this disease (7). Recent studies, however, have
failed to demonstrate with any definitive proof that selegiline
is neuroprotective with regard to idiopathic Parkinson’s
disease (3-5,7).
Selegiline alone is well tolerated; insomnia and anxiety
are the most commonly cited side effects. At recommended
doses, selegiline is not associated with the potential for
eliciting a hypertensive crisis as seen with the non-selective
MAO inhibitors used in the treatment of depression. At
doses of 10 mg/day or less, selegiline does not inhibit the
metabolism of peripheral catecholamines or exogenous indirect acting sympathomimetics such as tyramine found in
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certain drinks and foods (wine, cheese). However, at doses
above 10 mg/day, selegiline loses its selectivity for MAO-B
and may produce this reaction. In addition, selegiline, like
the non-selective MAO inhibitors, has been observed to
produce hyperthermia and convulsions following administration of the opioid analgesic meperidine (Demerol®)(5).
In early stages of Parkinson’s disease, selegiline may be
used alone. More commonly, it is used in combination with
L-DOPA because it allows for a lowering of the dose of LDOPA as well as increasing the time between doses. It is of
limited value, however, in patients with advanced Parkinson’s
disease (5).
Patient Scenario
Sy Kosis is a 72 year old male diagnosed with
Parkinson’s disease six years ago. He is fairly well
controlled with current therapy but complains of
some “good days and some bad days.” His daughter
is concerned about him taking diphenhydramine (25
mg) for his allergies. Will the diphenhydramine be
beneficial, harmful or have no effect with regard to
the symptoms of Parkinson’s disease in this patient?
Are there any other concerns about the use of
diphenhydramine in this patient?
POTENTIAL NEW THERAPIES

Glutamate is the major excitatory neurotransmitter in the
CNS. Recent research has focused on the glutamate receptor as a site of drug action in the treatment of various
diseases including Parkinson’s disease, schizophrenia, epilepsy and stroke. Given that glutamate is one of the excitatory
neurotransmitters in the striatum, it has been suggested that
blockade of glutamate transmission may be beneficial in the
treatment of Parkinson’s disease (6, 11). For example, in
some animal models of Parkinson’s disease, glutamate antagonists can relieve some of the signs and symptoms of the
disease. The dose of L-DOPA needed to alleviate these
signs can be dramatically reduced by combining L-DOPA
with a glutamate antagonist. MPTP-induced Parkinsonism
can be prevented by pretreating with glutamate antagonists(6-8,ll). Lamotrigine, an anticonvulsant that inhibits
the release of glutamate, may be helpful in improving some
of the clinical signs and symptoms of Parkinson’s disease (12).
Study Question
Use a diagram similar to the one in Figure 2 to show
the imbalance that exists between dopamine and
glutamate and describe the mechanism of drugs that
may restore this imbalance.

The information below is provided in a handout at the
end of the lecture series on Parkinson’s disease. The students are asked to consider the study problem and be ready
to discuss their answers following a live demonstration of
the model in class the following week.
RAT MODEL OF PARKINSON’S DISEASE

The nigrostriatal tract is a major pathway in the basal
ganglia that controls posture and movement. The cell bodies
of these neurons lie in the substantia nigra and the axons
project to the striatum where the nerve terminals release
dopamine. Dopamine activates postsynaptic dopamine receptors located in the striatum. Loss or destruction of the
nigrostriatal neurons appears to be the cause of movement

problems in Parkinson’s disease. Note that there are two
nigrostriatal tracts in the brain (both humans and rats); one
on the left side and one on the right side.
In the rat model of Parkinson’s disease, the neurotoxin
6-hydroxydopamine (6-OHDA) is injected into the right
side of the brain of a normal rat. The 6-OHDA is taken up
into nerve terminals that have reuptake mechanisms for
dopamine. Once inside the cell, 6-OHDA kills the entire
neuron - cell body, axon and nerve terminal. Cell death
occurs within 24^48 hours. At this point, the dopamine
receptors in the right striatum are receiving no input; the
nerves that release dopamine are absent. The striatum (post
synaptic cell) adapts by making more dopamine receptors
(upregulating or supersensitization). The left side of the
brain did not receive the toxin and the receptors and neurons remain unchanged (normal). There is now an imbalance of dopamine receptors between the left striatum and
the right striatum.
If a full dopamine agonist is administered systemically
(PO, IV or SC) to a normal rat, the rat’s response will be an
increase in motor activity — mostly sniffing, gnawing and
random movement in its cage. If a full dopamine agonist is
administered systemically to a rat previously injected with 6OHDA into the right side of the brain, the rat’s motor
behavior will be a constant circling to the left.
1. Draw and label the neuronal connections of the left and
right nigrostriatal pathways of a rat receiving an injection of 6-OHDA into the right side of the brain.
2. Which side of the brain is receiving greater stimulation
of dopamine receptors when a full dopamine agonist is
administered systemically? Why?
3. If the rat circles to the left when a full dopamine agonist
is administered, which direction will it turn if amphetamine is given systemically to the same rat? Why?
(Amphetamine causes the release of dopamine from
nerve terminals.)
4. What direction will the rat turn if a dopamine reuptake
inhibitor is administered systemically?
CONCLUSION

The intent of the above information is to provide a clear and
organized overview of the drug therapy for Parkinson’s
disease with the opportunity to reinforce the material through
discussions and problem solving exercises. The student
evaluations for this portion of the course have been overwhelming positive. Students indicate that the patient scenarios are helpful in understanding the connection between
the pharmacology of the drugs and their therapeutic applications. The scenarios also provide the students a break
from the didactic lecture and give them a chance to reflect on
the material and ask other related questions. The demonstration of the Parkinsonian rat model has also been viewed
very favorably. The pharmacotherapeutics sequence is taught
without a laboratory and, therefore, this demonstration
(and others occurring later in the sequence) offers another
useful method of reinforcing material.
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